Targeting tumor microenvironment in ovarian cancer: Premise and promise

Yuting Jiang; Chengdi Wang; Shengtao Zhou

doi:10.1016/j.bbcan.2020.188361

Targeting tumor microenvironment in ovarian cancer: Premise and promise

Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188361. doi: 10.1016/j.bbcan.2020.188361. Epub 2020 Mar 29.

Authors

Yuting Jiang¹, Chengdi Wang², Shengtao Zhou³

Affiliations

¹ Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, PR China.
² Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu 610041, China.
³ Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, PR China. Electronic address: shengtaozhou@scu.edu.cn.

PMID: 32234508
DOI: 10.1016/j.bbcan.2020.188361

Abstract

Ovarian cancer is the leading cause of gynecological cancer-related mortality globally. The majority of ovarian cancer patients suffer from relapse after standard of care therapies and the clinical benefits from cancer therapies are not satisfactory owing to drug resistance. Certain novel drugs targeting the components of tumor microenvironment (TME) have been approved by US Food and Drug Administration in solid cancers. As such, the passion is rekindled to exploit the role of TME in ovarian cancer progression and metastasis for discovery of novel therapeutics for this deadly disease. In the current review, we revisit the recent mechanistic insights into the contributions of TME to the development, progression, prognosis prediction and therapeutic efficacy of ovarian cancer via modulating cancer hallmarks. We also explored potentially promising predictive and prognostic biomarkers for ovarian cancer patients.

Keywords: Growth; Immune cells; Metastasis; Ovarian cancer; Stromal cells; Tumor microenvironment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adaptive Immunity / drug effects
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / analysis*
Clinical Trials as Topic
Disease Progression
Drug Approval
Female
Humans
Immunity, Innate / drug effects
Ovarian Neoplasms / diagnosis
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Prognosis
Progression-Free Survival
Tumor Escape / drug effects
Tumor Microenvironment / drug effects*
Tumor Microenvironment / immunology
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents
Biomarkers, Tumor